Showing 6891-6900 of 7603 results for "".
- Sandoz Proposed Biosimilar Shows Equivalent Efficacy to Humirahttps://practicaldermatology.com/news/sandoz-proposed-biosimilar-shows-equivalent-efficacy-to-humira/2458256/Sandoz’s proposed biosimilar adalimumab (GP2017) shows equivalent efficacy to reference medicine, according to data presented at the American Academy of Dermatology (AAD) in Orlando, Florida. The primary endpoint of the study was the proportio
- New Research Highlights Need for Greater Sun Safety Educationhttps://practicaldermatology.com/news/new-research-highlights-need-for-greater-sun-safety-education/2458261/Taken together, two new studies provide a mixed bag of news on the effectiveness of public health measures and messages aimed at decreasing skin cancer risk and improving sun safety behaviors. One study show
- Galderma Moves to Differentiate Their Two New HA Fillers From The Frayhttps://practicaldermatology.com/news/galderma-moves-to-differentiate-their-two-new-ha-fillers-from-the-fray/2458262/With a growing number of hyaluronic acid (HA) fillers available and even more in the pike, Galderma is highlighting how their two newest fillers --Restylane Refyne and Restylane Defyne --stand out from the crowd. In a word: flexibility. Th
- Galderma and Colorescience Launch Collaborationhttps://practicaldermatology.com/news/galderma-and-colorescience-launch-collaboration/2458265/Galderma will collaborate with Colorescience to expand skincare solutions to individuals who seek innovative daily skincare products that can be used in conjunction with traditional facial injectable aesthetic treatments, the companies have announced. Galderma and Color
- Skin Diseases Remain Major Cause of Disabilityhttps://practicaldermatology.com/news/skin-diseases-remain-major-cause-of-disability/2458267/Skin diseases are the fourth leading cause of disability worldwide, according to the Global Burden of Disease 2013 Study which appears online in JAMA Dermatology. For the study, researchers estimate
- Suzanne Olbricht, MD, Named New Chief of Dermatology at Beth Israel Deaconess Medical Centerhttps://practicaldermatology.com/news/suzanne-olbricht-md-named-new-chief-of-dermatology-at-beth-israel-deaconess-medical-center/2458278/Suzanne Olbricht, MD, is the new Chief of Dermatology at Beth Israel Deaconess Medical Center (BIDMC) in Boston. She will also serve as President of the American Academy of Dermatology in 2018. From 1983 to 1997, Dr. Olbricht worked as a staff derma
- Deadline Extended for Medical Spa State of the Industry Statistical Studyhttps://practicaldermatology.com/news/deadline-extended-for-medical-spa-state-of-the-industry-statistical-study/2458280/The American Med Spa Association (AmSpa) has extended the deadline for the 2017 Medical Spa St
- No Biopsy Required? Non-Invasive Skin Cancer Test May Offer Quick Diagnosishttps://practicaldermatology.com/news/no-biopsy-required-non-invasive-skin-cancer-test-may-offer-quick-diagnosis/2458284/A new non-invasive imaging technique may accurately detect skin cancer without surgical biopsy. Multiphoton microscopy of mitochondria accurately identified melanomas and basal cell carcinomas by detecting abnormal clusters of mitochondria in both types of skin cancer, according to resear
- New From Skinceuticals: H.A. Intensifierhttps://practicaldermatology.com/news/new-from-skinceuticals-ha-intensifier/2458285/SkinCeuticals is rolling out their new H.A. Intensifier, a corrective hyaluronic acid serum. Key ingredients include 10% Proxylane, a proprietary ingredient, to support hyaluronic acid levels and
- Ray Canole is New Chief Commercial Officer at Revision Skincarehttps://practicaldermatology.com/news/ray-canole-is-new-chief-commercial-officer-at-revision-skincare/2458287/Revision Skincare has announced the appointment of Ray Canole to the position of Chief Commercial Officer. He has over 15 years of business development and commercial related experience in dermatology-focused organizations and joins Revision from Renaissance Pharma, where he helped